Keyword: Regeneron Pharmaceuticals
Amgen lightens the mood in a new TV ad for cholesterol med Repatha even as Amgen continues a patent dispute and price drops for the drug.
Look out, Roche and Regeneron. Thanks to an FDA priority review, Novartis eye candidate brolucizumab could start stealing sales in October.
After two straight years at number 12 on FiercePharma’s list of the top pharma companies by revenues, Amgen moved up one spot with 2018 sales of $23.75 billion.
As Bayer completed the gigantic Monsanto crop science buyout in summer 2018, it started a large overhaul that will cut its animal health business, some consumer health brands and 10% of its workforce.
Dupixent is now the first FDA-approved biologic for adolescents with eczema—and it's on the priority review track for adult sinusitis, too.
Give the latest round of the PCSK9 patent fight to Amgen. A jury backed two key patents that Sanofi and Regeneron have admitted they infringed.
After launching at about the same price—$14,000-plus—Praluent and Repatha again stand on par. But this time, it’s less than half the original sticker.
Regeneron's CEO calls Libtayo “the engine that could.” And Wednesday, those wondering, “could what?” got a glimpse at what the drug has done so far.
It wasn't just deals folks were buzzing about in meeting rooms, restaurants and hotel lobbies, as our top FierceBiotech and FiercePharma stories show.
Investors had been worried that growth for Regeneron’s Eylea was slowing down, but Monday the company batted away those fears.